NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, February, 5th. The company reported $0.45 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.37 by $0.08. The firm earned $623 million during the quarter, compared to analysts' expectations of $608.38 million. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The business's revenue was up 2.8% on a year-over-year basis. During the same period last year, the firm posted $0.45 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Catalent.

Catalent will be holding an earnings conference call on Tuesday, May 7th at 8:15 AM Eastern. Interested parties can register for or listen to the call using this link.

Catalent updated its FY 2019 earnings guidance on Tuesday, February, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.5-2.59 billion, compared to the consensus revenue estimate of $2.51 billion.

7 analysts have issued 1 year price objectives for Catalent's shares. Their predictions range from $45.00 to $55.00. On average, they expect Catalent's share price to reach $50.50 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Price Targets for Catalent.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

Media stories about CTLT stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catalent earned a daily sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Some companies that are related to Catalent include BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Marina Biotech (MRNA), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO) and Beigene (BGNE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Energy Transfer LP Unit (ET), Abbott Laboratories (ABT), AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Micron Technology (MU), Alibaba Group (BABA) and CBL & Associates Properties (CBL).

Catalent's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Retirement Systems of Alabama (0.13%), Louisiana State Employees Retirement System (0.03%), Meeder Asset Management Inc. (0.02%), Nisa Investment Advisors LLC (0.02%), Sciencast Management LP (0.01%) and Oakbrook Investments LLC (0.01%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, John J Greisch, John R Chiminski, Lance Miyamoto, Sharon Johnson, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Virtu Financial LLC, First Hawaiian Bank, Strs Ohio and New England Research & Management Inc.. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Sciencast Management LP, We Are One Seven LLC, Nisa Investment Advisors LLC, Financial Gravity Wealth Inc., Retirement Systems of Alabama, First Bank & Trust, Sageworth Trust Co and Louisiana State Employees Retirement System. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $43.97.

Catalent has a market capitalization of $6.40 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

The official website for Catalent is http://www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]